acenocoumarol and Glomerulonephritis

A controlled therapeutic study was carried out on 38 patients with IgA glomerulonephritis. According to the data from the light microscopy, 15 patients were with minimum histological deviations, 21 patients--with focal-segmental glomerulonephritis, and 2 patients--with diffuse. The patients with the minimum histological deviations and focal-segmental glomerulonephritis were grouped into three groups. The first group of 13 patients was treated with indomethacin, 75 mg daily in the course of 8.5 months on the average (6-13 months). The second group of 5 patients was treated with levamisole--3 days with 150 mg daily--two times a month, in the course of 14 months on the average (6.5-30 months). The control group, without any treatment, covered 13 patients. There were no discrepancies in the clinical manifestations, laboratory data and renal function among the patients from the three groups. In an additional group of 7 patients with focal-segmental and diffuse mesangioproliferative glomerulonephritis, five of them with renal insufficiency, a combined immuno-suppressive and anticoagulant treatment with azathioprin, heparin and acenocoumarol was carried out in the course of 15 months on the average (6-35 months). Indomethacin and levamisole treatment had no effect on the clinical manifestations and evolution of the disease. The combined immuno-suppressive and anticoagulant treatment had also no effect on the progress in the terminal renal insufficiency.

Topics: Acenocoumarol; Adolescent; Adult; Azathioprine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorescent Antibody Technique; Glomerulonephritis; Heparin; Humans; Immunoglobulin A; Indomethacin; Kidney Glomerulus; Levamisole; Male; Middle Aged

Topics: Acenocoumarol; Adult; Anticoagulants; Female; Glomerulonephritis; Humans; Lupus Erythematosus, Systemic

Topics: Acenocoumarol; Acute Disease; Adult; Azathioprine; Biopsy; Drug Therapy, Combination; Female; Glomerulonephritis; Heparin; Humans; Kidney Glomerulus; Male; Methylprednisolone; Middle Aged; Prednisone

Combined corticosteroid, immunosuppressive and anticoagulant treatment was performed to 17 patients with various histological forms of collagenous glomerulonephritis, 14--with disseminated lupus erythematodes, 1--with periartheritis nodosa and 2--with Schönlein-Henoch disease. The immunosuppressive treatment was carried out for an average of 14.62 months, the corticosteroid treatment--an average of 17 months and the anticoagulant--18.12 months. In 6 patients the corticosteroid treatment was initiated with a pulse of 30 mg methylprednisolone in the course of 3-10 days, and in the rest of the patients--with an initial dose of 60 mg prednisolone. The anticoagulant treatment was, at first, carried out with heparin 30,000 U daily, and later with acenocoumarol and the immunosuppressive--with azathioprin--100 mg daily. The term of treatment and observation is from 6 to 63 months, an average of 25-82 months. The treatment was discontinued in eight patients. Very good effect (complete clinical and laboratory remission) was obtained in seven patients--41.18 per cent, good effect (clinical remission but incomplete laboratory) in 7 patients--41.18 per cent, one patient with no change--5.88 per cent. Two patients--11.76 per cent, died of the complications of the treatment. Grave complications resulting from the treatment were obtained in seven patients.

Topics: Acenocoumarol; Adolescent; Adult; Azathioprine; Drug Therapy, Combination; Female; Glomerulonephritis; Heparin; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Prednisolone

Topics: Acenocoumarol; Allopurinol; Chloramphenicol; Chlorpropamide; Clofibrate; Glomerular Filtration Rate; Glomerulonephritis; Half-Life; Humans; Kidney; Kidney Diseases; Probenecid; Pyelonephritis